Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Prepaid Assets (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Prepaid Assets for 7 consecutive years, with $44.1 million as the latest value for Q4 2025.

  • Quarterly Prepaid Assets rose 26.39% to $44.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $44.1 million through Dec 2025, up 26.39% year-over-year, with the annual reading at $44.1 million for FY2025, 26.39% up from the prior year.
  • Prepaid Assets hit $44.1 million in Q4 2025 for BridgeBio Pharma, down from $52.4 million in the prior quarter.
  • In the past five years, Prepaid Assets ranged from a high of $60.2 million in Q2 2025 to a low of $20.5 million in Q2 2023.
  • Historically, Prepaid Assets has averaged $32.3 million across 5 years, with a median of $30.2 million in 2021.
  • Biggest five-year swings in Prepaid Assets: plummeted 37.27% in 2023 and later skyrocketed 112.14% in 2025.
  • Year by year, Prepaid Assets stood at $32.3 million in 2021, then crashed by 32.06% to $21.9 million in 2022, then rose by 10.87% to $24.3 million in 2023, then soared by 43.46% to $34.9 million in 2024, then grew by 26.39% to $44.1 million in 2025.
  • Business Quant data shows Prepaid Assets for BBIO at $44.1 million in Q4 2025, $52.4 million in Q3 2025, and $60.2 million in Q2 2025.